LSV Asset Management Grows Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

LSV Asset Management increased its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 16.4% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 181,308 shares of the biotechnology company’s stock after buying an additional 25,608 shares during the period. LSV Asset Management owned about 0.08% of ADMA Biologics worth $2,027,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in ADMA. Viewpoint Capital Management LLC raised its stake in ADMA Biologics by 18.6% in the 1st quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 2,416 shares during the last quarter. Arizona State Retirement System raised its stake in ADMA Biologics by 4.5% in the 2nd quarter. Arizona State Retirement System now owns 61,641 shares of the biotechnology company’s stock valued at $689,000 after purchasing an additional 2,645 shares during the last quarter. Eagle Asset Management Inc. raised its stake in ADMA Biologics by 20.2% in the 4th quarter. Eagle Asset Management Inc. now owns 25,957 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 4,367 shares during the last quarter. CWM LLC raised its stake in ADMA Biologics by 114.2% in the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 4,367 shares during the last quarter. Finally, ProShare Advisors LLC raised its stake in ADMA Biologics by 9.2% in the 1st quarter. ProShare Advisors LLC now owns 54,293 shares of the biotechnology company’s stock valued at $358,000 after purchasing an additional 4,570 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Stock Up 4.4 %

ADMA opened at $17.65 on Friday. The firm has a 50 day moving average price of $14.81 and a 200 day moving average price of $10.31. The company has a market cap of $4.09 billion, a PE ratio of -882.50 and a beta of 0.61. ADMA Biologics, Inc. has a 1 year low of $3.06 and a 1 year high of $19.34. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. The firm had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. ADMA Biologics’s quarterly revenue was up 78.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.02) EPS. Sell-side analysts expect that ADMA Biologics, Inc. will post 0.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

ADMA has been the subject of several analyst reports. HC Wainwright boosted their target price on shares of ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Cantor Fitzgerald upped their price objective on shares of ADMA Biologics from $15.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Finally, Mizuho upped their price objective on shares of ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, June 20th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, ADMA Biologics currently has an average rating of “Buy” and a consensus target price of $15.50.

Insiders Place Their Bets

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the transaction, the director now owns 153,941 shares in the company, valued at approximately $2,843,290.27. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Young Kwon sold 60,000 shares of the stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the completion of the transaction, the director now directly owns 241,441 shares in the company, valued at approximately $4,408,712.66. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the transaction, the director now owns 153,941 shares of the company’s stock, valued at $2,843,290.27. The disclosure for this sale can be found here. Insiders sold a total of 466,900 shares of company stock worth $8,224,121 in the last 90 days. 3.70% of the stock is owned by company insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.